1Jemal A, Tiwari RC, Murray T,et al. American Cancer Society Cancer statistics. CA Cancer J Clin,2004,54:8 - 29. 被引量：1
2Prostate Cancer Tfiallists' Collaborative Group Maximumandrogen blockade in advanced prostate cancer: an overview of therandomised trials. Lancet ,2000,355 : 1491 - 1498. 被引量：1
3D' Amieo AV, Manola J, Loffredo M,et al. Kantoff PW 2004 6 -Month androgen suppression plus radiationtherapy vs. radiation therapy alone for patients with clinicallylocalized prostate cancer: a randomized controlled trial. JAMA,2001292:821 - 827. 被引量：1
4Hanks GE, Lu J, Machtay M. RTOG Protocol 92 - 02 : APhase Ⅲ trialof the use of long term androgen suppression following neoadjuvanthormonal cytoreduction and radiotherapy in locally advancedcareinoma of the prostate. Proc 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, 2000, p128 -4112. 被引量：1
5Iversen P, Tyrrell CJ, Kaisary AV,et al. Melezinek I Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol,2000,164 : 1579 - 1582. 被引量：1
6Peto R, Dalesio O. Breast and prostate cancer: 10 - year survival gains in the hormonal adjuvant treatment trims. Prec 12th European Conference on Clinical Oncology, Copenhagen, Denmark, 2003,p101. 被引量：1
7Labile F, Candas B, Gomez JL. Cusan L Can combined androgen blockade provide long - term control or possible cure of localized prostate cancer? Urology,2002,60 : 115 - 119. 被引量：1
8Labile F. Prostate cancer and combined androgen blockade at all stages of disease. In: Khayat D, Hortobagyi GN, eds. Progressin anti - cancer chemotherapy. France, Berlin, Heidelberg: Springer; 2000 :171 - 187. 被引量：1
9Labile F 2000 Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support. Prostate,2003,43:215 -222. 被引量：1
10Roy J, Couillard S, Gutman M, Labile FA novel pure SERM achieves complete regression of the majority of human breast cancer tumors in nude mice. Breast Cancer Res Treat2002,81:223 -229. 被引量：1
